OBX· Health Care› Biotechnology

Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. More about the company

$13.94

+0.07% today

$861M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

—

Edge

—

Is OBX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-07-27 → 2026-10-22

S? 13w

2026-07-272026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 13w current

Total tracked: 13 weeks across 1 stage run.

OBX among Biotechnology591st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…591	OBXObsidian Therapeutics, Inc.	—	—	−8.7%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 13

1w13w26w

Week 13, proven structure

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.39x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-8.7%

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 13 · Vol 0.39x

2026-10-21S—

Wk 13 · Vol 0.72x

2026-10-20S—

Wk 13 · Vol 0.95x

2026-10-19S—

Wk 12 · Vol 0.25x

2026-10-16S—

Wk 12 · Vol 0.70x

2026-10-15S—

Wk 12 · Vol 0.57x

2026-10-14S—

Wk 12 · Vol 0.72x

2026-10-13S—

Wk 12 · Vol 0.92x

2026-10-12S—

Wk 11 · Vol 1.05x

2026-10-09S—

Wk 11 · Vol 1.37x

2026-10-08S—

Wk 11 · Vol 1.36x

2026-10-07S—

Wk 11 · Vol 0.97x

Moving averages & range

50 DMA

$15.86

200 DMA

—

52W High

—

52W Low

—

5D Low

$11.77

Resistance levels (recent highs)

20d High

$14.58

60d High

$35.00

120d High

—

250d High

—

Next resistance

+4.6%

to 20d High

Dividend Yield

0.00%

P/B -1.0

Obsidian Therapeutics: quick answers

Which sector and industry is Obsidian Therapeutics in?

Obsidian Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.